CRBU Caribou Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRBU

Price (delayed)

$3.77

Market cap

$340.49M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.38

Enterprise value

$316.43M

Highlights
The revenue has surged by 149% year-on-year
CRBU's gross profit has soared by 149% YoY
The quick ratio is up by 32% year-on-year but it is down by 16% since the previous quarter
The equity rose by 22% YoY but it fell by 7% QoQ
Caribou Biosciences's net income has decreased by 8% QoQ and by 2.7% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of CRBU
Market
Shares outstanding
90.31M
Market cap
$340.49M
Enterprise value
$316.43M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.9
Price to sales (P/S)
8.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.18
Earnings
Revenue
$34.48M
EBIT
-$101.88M
EBITDA
-$96.3M
Free cash flow
-$104.9M
Per share
EPS
-$1.38
Free cash flow per share
-$1.42
Book value per share
$4.17
Revenue per share
$0.47
TBVPS
$5.86
Balance sheet
Total assets
$432.21M
Total liabilities
$63.81M
Debt
$27.11M
Equity
$368.4M
Working capital
$310.54M
Liquidity
Debt to equity
0.07
Current ratio
11.97
Quick ratio
11.7
Net debt/EBITDA
0.25
Margins
EBITDA margin
-279.3%
Gross margin
100%
Net margin
-296.1%
Operating margin
-336.6%
Efficiency
Return on assets
-25.7%
Return on equity
-31.1%
Return on invested capital
-31.2%
Return on capital employed
-25.2%
Return on sales
-295.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRBU stock price

How has the Caribou Biosciences stock price performed over time
Intraday
3.57%
1 week
1.62%
1 month
-19.44%
1 year
-12.93%
YTD
-34.21%
QTD
-26.65%

Financial performance

How have Caribou Biosciences's revenue and profit performed over time
Revenue
$34.48M
Gross profit
$34.48M
Operating income
-$116.06M
Net income
-$102.07M
Gross margin
100%
Net margin
-296.1%
The revenue has surged by 149% year-on-year
CRBU's gross profit has soared by 149% YoY
Caribou Biosciences's net margin has soared by 59% YoY but it has decreased by 8% from the previous quarter
The company's operating margin has surged by 56% YoY but it fell by 7% QoQ

Growth

What is Caribou Biosciences's growth rate over time

Valuation

What is Caribou Biosciences stock price valuation
P/E
N/A
P/B
0.9
P/S
8.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.18
Caribou Biosciences's EPS has increased by 16% YoY and by 9% QoQ
The equity rose by 22% YoY but it fell by 7% QoQ
The P/B is 18% less than the last 4 quarters average of 1.1
The revenue has surged by 149% year-on-year
CRBU's P/S is 50% below its last 4 quarters average of 16.1

Efficiency

How efficient is Caribou Biosciences business performance
Caribou Biosciences's return on sales has surged by 59% YoY but it has decreased by 8% QoQ
CRBU's ROA is down by 6% year-on-year and by 4% since the previous quarter
The ROE has contracted by 5% YoY and by 2.6% from the previous quarter
CRBU's return on invested capital is up by 2.8% year-on-year but it is down by 2.6% since the previous quarter

Dividends

What is CRBU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRBU.

Financial health

How did Caribou Biosciences financials performed over time
The quick ratio is up by 32% year-on-year but it is down by 16% since the previous quarter
The current ratio has grown by 29% YoY but it has contracted by 16% from the previous quarter
Caribou Biosciences's debt is 93% less than its equity
The equity rose by 22% YoY but it fell by 7% QoQ
Caribou Biosciences's debt to equity has decreased by 22% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.